COMMENTARY

• Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
  March 26, 2012

• Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
  March 19, 2012

• Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
  March 13, 2012

• Further Provisions Required – One Year since the Great East Japan Earthquake
  March 12, 2012

• Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
  March 5, 2012

• Will Wholesalers Be Able to Succeed at Reform This Time?
  February 20, 2012

• Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
  January 23, 2012

• Will New Drug Makers Dominate Domestic Biosimilars Market?
  December 26, 2011

• Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
  December 12, 2011

• “Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
  November 28, 2011

• Perpetuation of Premium for New Drug Development Faces Hurdles
  November 14, 2011

• Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
  November 14, 2011

• Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
  October 19, 2011

• Pinning Hope on Academia in Seeking a Radical Cure for AD
  October 10, 2011

• New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
  October 3, 2011

• Discussions on Amendment of PAL Now in Final Stages
  October 3, 2011

• Korosho Revises GL for Drafting, Distributing Drug Safety Information
  September 5, 2011

• Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
  August 29, 2011

• Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
  August 8, 2011

• Current Promising Drug Candidates with a New Mode of Action
  August 8, 2011

ページ